JPRO
  • Home
    • English Top
    • 日本語トップ
  • Table of Contents (English)
  • コンテンツ一覧

Advanced Medical Care System

Japan's Advanced Medical Care System is one type of "Evaluation-Based Medical Care" (Hyoka Ryoyo) conducted to evaluate future inclusion in public health insurance. It is broadly divided into "Advanced Medical Care A" (formerly Class II Advanced Medical Care) and "Advanced Medical Care B" (formerly Class III Advanced Medical Care) based on the novelty of the technology and the degree of evaluation required.

Advanced Medical Care A
: Targets technologies whose effectiveness and safety have been established to a certain extent, without involving the use of unapproved pharmaceuticals or medical devices. This includes cases such as applying existing technology to new surgical procedures.

Advanced Medical Care B: Targets extremely novel medical technologies that involve the use of unapproved pharmaceuticals or medical devices, or even without them, are judged to require particularly focused observation and evaluation regarding their implementation, implementation environment, technological effects, etc., in consideration of the technology's safety and effectiveness.

Reference Materials
  • Overview of Advanced Medical Care | Ministry of Health, Labour and Welfare https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/sensiniryo/index.html
  • Regarding the Advanced Medical Care Evaluation System (Draft) https://www.mhlw.go.jp/shingi/2008/03/dl/s0312-12f.pdf
  • Advanced Medical Care Program for the Rapid Introduction of Healthcare Technologies to the National Health Insurance System in Japan - PMC (english)


Overview from the Patient's Perspective
Purpose and Merits: This is a system that allows patients to receive advanced, high-level medical technologies—which are being considered for future public health insurance coverage—in combination with treatments already covered by insurance. This enables access to the latest treatments that are not yet widely available.
Cost Burden: The technical fees for advanced medical care are entirely borne by the patient (out-of-pocket). However, parts common to standard treatment, such as consultations, examinations, medications, and hospitalization fees, are covered by public health insurance. Some local governments may have subsidy programs for the out-of-pocket portion of advanced medical care.
Procedure: Before receiving treatment, patients must receive a full explanation of the treatment content and costs from the medical institution, understand it, and sign a consent form.

​
Overview from the Medical Technology Provider’s Perspective
Purpose and Positioning: This is an important step aimed at achieving future insurance reimbursement (coverage by public health insurance) for newly developed medical technologies (including unapproved pharmaceuticals and medical devices). Through this system, data is collected to evaluate the technology's effectiveness and safety in actual clinical settings.
Merits: At the pre-insurance-coverage stage, the technology can be clinically introduced at limited medical institutions, building a track record in society. The data obtained here becomes important evidence for future insurance reimbursement applications.
Procedures and Requirements: To be approved as advanced medical care, an application must be submitted to the Ministry of Health, Labour and Welfare, and it must undergo a rigorous review by an expert panel. The review evaluates not only "technical validity," such as the technology's effectiveness and safety, but also "social validity," including ethics and diffusibility. Particularly for "Advanced Medical Care B," which targets highly novel technologies, focused observation and evaluation are required.


Consultation Desks
The responsible departments at the MHLW are the Medical Care Division, Health Insurance Bureau, and the Advanced Medical Care Section, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare.
  • Prior Consultation Application Form for Advanced Medical Care https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryou/koudoiryou-hyouka/dl/moushikomi.pdf
In addition, multiple medical institutions are listed as consultation desks, mainly for researchers.
  • soudan.pdf https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/sensiniryo/minaoshi/dl/soudanB.pdf
    • Many of these medical institutions are also Core Clinical Research Hospitals.


​@K.Kamitani
Table of Contents 
About ​JPRO

​
Services
Contact Us
​​コンテンツ一覧
​
オフィス概要

【免責事項】
本サイトに掲載する情報は、厚生労働省、経済産業省、PMDA等の公的機関が発行する一次資料に基づき、正確性を期して作成していますが、その完全性、正確性、最新性を保証するものではありません。法規制は改正されることがあり、掲載情報が最新でない場合があります。本サイトの情報は一般的な情報提供を目的としたものであり、個別の薬事・法務・知財・税務等に関する専門的助言に代わるものではありません。具体的な判断や手続きにあたっては、必ず所管の規制当局または専門家にご確認ください。本サイトの情報に基づいて行われたいかなる行為についても、JPROは一切の責任を負いません。

【Disclaimer】
The information on this site is based on primary sources issued by Japanese government agencies (MHLW, METI, PMDA, etc.) and is prepared with the aim of accuracy. However, JPRO does not guarantee its completeness, accuracy, or currency. Regulations are subject to change, and the information may not reflect the latest amendments. The content is provided for general informational purposes only and does not constitute professional advice on regulatory, legal, intellectual property, or tax matters. For specific decisions or procedures, always consult the relevant regulatory authorities or qualified professionals. JPRO assumes no liability for any actions taken based on the information provided on this site.

本サイトは、主にヘルスケア領域での起業・社会実装を目指す方のための情報サイトです。公的機関でアドバイザーを務める著者が、起業家が十分な知識を持ち、外部に過度に依存せず主体的に事業化を進められるよう、プロボノ活動の一環として運営しています。薬事等の法規制から資金調達、事業開発、知財など必要な情報をワンストップで収集できます。掲載情報は信頼性の高い公的機関の一次資料に基づいています。
This portal supports international healthcare enterprises and innovators expanding into the Japanese market. Operated as a pro bono initiative by an advisor to Japanese public institutions, the site is designed to equip you with the knowledge needed to advance your business proactively, without over-reliance on external consultants. From regulatory affairs to business setups, all content is sourced only from highly reliable public institutions. ©2026 JPRO
  • Home
    • English Top
    • 日本語トップ
  • Table of Contents (English)
  • コンテンツ一覧